Approval · Notice of Compliance 20747 · 2018

RIXUBIS: Notice of Compliance 20747

Issued April 13, 2018

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 20747
Date: April 13, 2018
Company: Shire Pharma Canada UlcToronto, Ontario, Canada
Product type: Biologic
Submission: New Drug Submission (NDS)
Submission class: Admin

Products in this notice

Brand	DIN	Status today
RIXUBIS	02431920	Dormant
RIXUBIS	02431939	Dormant
RIXUBIS	02431947	Marketed
RIXUBIS	02431955	Marketed
RIXUBIS	02431963	Marketed

Medicinal ingredients

NONACOG GAMMA 250 UNIT per VIAL
NONACOG GAMMA 500 UNIT per VIAL
NONACOG GAMMA 1,000 UNIT per VIAL
NONACOG GAMMA 2,000 UNIT per VIAL
NONACOG GAMMA 3,000 UNIT per VIAL